Korsana Biosciences, Inc. KRSA
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +259.51%
- 1 year
- +145.47%
- Market cap
- 1.46B
- EPS (ttm)
- -7.07
- Shares out
- 45.54M
- Forward P/E
- -8.99
- YTD return
- +259.51%
- 1-year return
- +145.47%
- Volume
- 152.10K
- Avg volume
- 75.45K
- Open
- 32.13
- Previous close
- 31.66
- Day's range
- 31.66 – 33.23
- 52-week range
- 7.19 – 59.36
- Beta
- 1.84
- Analysts
- Strong Buy
- Price target
- 44.00 (+37.7%)
- Earnings date
- Nov 11, 2026
5Y -373.06 (-92.52%)
Key statistics
- Enterprise value
- 232.43M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 134.16M
- Total debt
- 1.10M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 31.17
- 200-day average
- 22.06
Analyst view
Consensus: strong buy
- Target (low)
- 8.00
- Target (mean)
- 44.00
- Target (high)
- 70.00
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.84695 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -3.45 | -0.41 | +3.04 | +88.12% |
| May 5, 2026 | Mar 31, 2026 | -2.66 | -2.66 | 0.00 | 0.00% |
| Mar 17, 2026 | Dec 31, 2025 | -2.66 | -1.75 | +0.91 | +34.21% |
| Nov 12, 2025 | Sep 30, 2025 | -121.80 | -0.30 | +121.50 | +99.75% |
| Aug 5, 2025 | Jun 30, 2025 | — | -0.11 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | Wedbush | init | — | Outperform |
| Sep 28, 2026 | Guggenheim | init | — | Buy |
| Sep 14, 2026 | Stifel | init | — | Buy |
| Sep 14, 2026 | TD Cowen | init | — | Buy |
| Sep 11, 2026 | UBS | init | — | Buy |
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- korsana.com
News
Your note
Sign in to keep a note on KRSA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHICKO RHONDA M. CPA | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 25,018 |
| GRAUL REGINA MARGARET | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 107,523 |
| HECHT PETER M | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 15, 2026 | 910,312 |
| HIGGINS MICHAEL J | Director | Stock Award(Grant) | Mar 24, 2025 | 30,740 |
| SLATE PATH CAPITAL LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 20, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kalehua Capital Management LLC | 0.52% | 235,907 | 7.54M | Jun 29, 2026 |
| FMR, LLC | 0.20% | 92,793 | 2.97M | Jun 29, 2026 |
| Balyasny Asset Management LP | 0.10% | 45,359 | 1.45M | Jun 29, 2026 |
| Adar1 Capital Management, LLC | 0.09% | 42,680 | 1.36M | Jun 29, 2026 |
| Braidwell LP | 0.05% | 22,413 | 716.32K | Jun 29, 2026 |
| Citadel Advisors Llc | 0.02% | 8,542 | 273.00K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.07% | 31,141 | 995.27K | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.03% | 15,200 | 485.79K | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.02% | 8,668 | 277.03K | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.02% | 8,186 | 261.62K | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.01% | 4,416 | 141.13K | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.01% | 5,351 | 171.02K | Aug 30, 2026 |